Most analysts and doctors were expecting the FDA to seek additional information before approving Arcoxia because Merck pulled Vioxx from the market last month after a study showed it doubled patients risk of heart attacks and strokes.
The Vioxx withdrawal caused Merck's third quarter profit to fall 29 percent.
Health Canada has asked Pfizer for more safety data, Valois said.
Merck is scheduled to finish a 23,500 patient study that was designed to study cardiovascular safety in early 2006.
Vioxx has been taken by about 20 million Americans and had produced 11 percent of Merck's total revenues.
